Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The RX label does not recommend use at CrCl 15-29. NIH retains that recommendation but notes some Panel members continue full-dose FTC in this range to retain the fixed-dose regimen, with insufficient evidence for or against that practice.
Before applying: This is not blanket approval, a new-start rule, or permission to adjust a fixed-dose component independently. Obtain HIV specialist input and document the rationale.
Also check: GENVOYA: label restriction versus qualified NIH panel practice
Rxlist source
GlobalRPh RX List - Genvoya
Product / population
GENVOYA fixed-dose oral HIV regimen; adults and qualifying pediatric patients, with adult-only chronic-HD provision.
Renal measure
Estimated CrCl (mL/min); chronic hemodialysis.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
The source uses one tablet daily with food in adults or patients weighing at least 25 kg with CrCl >=30. Adult patients with CrCl below 15 receiving chronic hemodialysis may use the regimen; give after dialysis on treatment days. It is not recommended at CrCl 15 to below 30, or below 15 without chronic hemodialysis. Cobicistat can raise serum creatinine by inhibiting tubular secretion, but true renal injury also requires evaluation. Monitor renal function and urine measures as directed by the complete label; do not dismiss every creatinine increase as a benign transporter effect.
Source revision: September 2021, as printed in retrieved RX source. | Retrieved: 2026-09-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.
Find text within this drug
Find a term without leaving this drug
Search the stored clinical text
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
label vs professional guidance
GENVOYA: label restriction versus qualified NIH panel practice
The RX label does not recommend use at CrCl 15-29. NIH retains that recommendation but notes some Panel members continue full-dose FTC in this range to retain the fixed-dose regimen, with insufficient evidence for or against that practice.
How to use this: This is not blanket approval, a new-start rule, or permission to adjust a fixed-dose component independently. Obtain HIV specialist input and document the rationale.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Rxlist source
GlobalRPh RX List - Genvoya
GENVOYA fixed-dose oral HIV regimen; adults and qualifying pediatric patients, with adult-only chronic-HD provision.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
GlobalRPh-hosted RX List · GENVOYA fixed-dose oral HIV regimen; adults and qualifying pediatric patients, with adult-only chronic-HD provision.
Renal method: Estimated CrCl (mL/min); chronic hemodialysis. Source date: September 2021, as printed in retrieved RX source. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The source uses one tablet daily with food in adults or patients weighing at least 25 kg with CrCl >=30. Adult patients with CrCl below 15 receiving chronic hemodialysis may use the regimen; give after dialysis on treatment days. It is not recommended at CrCl 15 to below 30, or below 15 without chronic hemodialysis. Cobicistat can raise serum creatinine by inhibiting tubular secretion, but true renal injury also requires evaluation. Monitor renal function and urine measures as directed by the complete label; do not dismiss every creatinine increase as a benign transporter effect.
RDM39-rxlist-elvitegravir-cobicistat-ftc-taf-genvoya-c4cf881145-C1 · Source locator: Selected renal dosing, use in renal impairment, warnings and clinical pharmacology subsections; see named sections in summary.
NIH ClinicalInfo HIV guidelines · NIH adult/adolescent ARV table; GENVOYA row and its qualified FTC footnote only.
Renal method: CrCl (mL/min); chronic hemodialysis. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The GENVOYA row retains not-recommended wording at CrCl 15-29 and below 15 without hemodialysis. It also describes insufficient evidence for or against full-dose daily emtricitabine below CrCl 30: some Panel members retain full-dose FTC at 15-29 to allow continuation of the fixed-dose product. This is qualified expert practice, not a general endorsement or a new-initiation rule. On chronic hemodialysis, no adjustment is necessary; administer after dialysis on dialysis days. Review the whole regimen and interactions rather than adjusting one fixed-dose component independently.
Additional summaries stored on this page: 0 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.